Analyst Rating Update on Pacira Pharmaceuticals (PCRX)

Pacira Pharmaceuticals (NASDAQ:PCRX) : The consensus on Pacira Pharmaceuticals (NASDAQ:PCRX) based on 8 analyst recommendation on the company stock is 1.25, which is interpreted as a Strong Buy recommendation. Zacks Investment Research has issued a rank of 3 which endorses a Hold on the stock. However, 7 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 1 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating.

Pacira Pharmaceuticals (NASDAQ:PCRX) : The highest short term price target forecast on Pacira Pharmaceuticals (NASDAQ:PCRX) is $105 and the lowest target price is $59. A total of 8 equity analysts are currently covering the company. The average price of all the analysts is $78.13 with a standard deviation of $14.49.

For the current week, the company shares have a recommendation consensus of Buy.

Pacira Pharmaceuticals (NASDAQ:PCRX): stock turned positive on Tuesday. Though the stock opened at $38.56, the bulls momentum made the stock top out at $40 level for the day. The stock recorded a low of $38.1401 and closed the trading day at $38.88, in the green by 2.37%. The total traded volume for the day was 843,690. The stock had closed at $37.98 in the previous days trading.

In an insider trading activity,The director of Pacira Pharmaceuticals, Inc., Brege Laura sold 1,000 shares at $46.95 on June 6, 2016. The Insider selling transaction had a total value worth of $46,950. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.

Pacira Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is focused on the development, commercialization and manufacture of pharmaceutical products, based on its DepoFoam drug delivery technology, primarily for use in hospitals and ambulatory surgery centers. Its primary focus lies in the development of non-opioid products for postsurgical pain control. DepoFoam is basis for the companys lead product candidate, EXPAREL, a liposome injection of bupivacaine, an amide-type local anesthetic indicated for infiltration into the surgical site to produce postsurgical analgesia. In addition to EXPAREL, DepoFoam is also the basis for its other commercial product, DepoCyt(e), which the Company manufactures for its commercial partners, as well as its other product candidates. The Companys other product candidates include DepoMeloxicam and DepoTranexamic Acid.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.